Latest Headlines

Latest Headlines

Injectable HIV regimen being developed by J&J and ViiV Healthcare shows promise in trials

Johnson & Johnson's Janssen announced that a Phase IIb study of a combination regimen of two investigational long-acting injectable HIV drugs found that the therapy performed similarly to a regimen consisting of three oral medications.

Scientists make strides toward full-body PET scanner with $15.5M in tow

Researchers are developing the world's first total-body positron emission tomography (PET) scanning device to improve disease diagnosis and treatment.

Sanofi's back-to-growth strategy fails to impress analysts

If Sanofi CEO Olivier Brandicourt wanted to win over analysts with Friday's pronouncements about the company's future, he must be disappointed now. A slew of investment firms cut their price targets and several downgraded the shares, as the French drugmaker's strategy for future growth was outweighed by warnings about stagnant earnings for the next few years.

NIH, Medtronic-backed startup reports mixed Phase II deep brain stimulation data in Alzheimer's

Functional Neuromodulation, a startup backed by Medtronic and the National Institutes of Health, will advance its deep brain stimulation implant into a Phase III trial to treat Alzheimer's disease patients. DBS is a standard treatment for movement disorders, such as Parkinson's disease, but hasn't been widely applied to other brain disorders.

Sanofi CEO Brandicourt's first lead role booed by analysts

Olivier Brandicourt got his first shot at Sanofi's lead role in an annual investor day, and the reviews are not good. Brandicourt had a tough message to sell. The company's diabetes franchise is getting hammered, with the all-important Lantus business weakening, which means that R&D as well as SG&A are going to eat up a higher percentage of revenue for at least a couple of years.

Academic vets make strides in ongoing fight against deadly pig viruses

Some pigs are born with tremors that are so serious they can't nurse properly. The shakes, which can lead to malnutrition and starvation, come from a virus that's been recognized for nearly 100 years but had never been defined--until now.

Under Pfizer's gaze, Allergan's Saunders softens his tone on early-stage R&D

Allergan CEO Brent Saunders, who once called Big Pharma's perceived need for drug discovery "a fallacy," has come around on early-stage research, a change in tone that happens to coincide with Pfizer's stated interest in buying his company.

Transcriptic adds CRISPR gene editing to robotic lab

Transcriptic has added CRISPR gene editing to the list of services provided by its robotic laboratory. The service expansion is being supported by Desktop Genetics, a developer of gene-editing software that is making its CRISPR library design algorithms available to Transcriptic.

Flush with $90M in VC cash, Twist and Ginkgo strike massive synthetic DNA deal

Ginkgo Bioworks and Twist Bioscience have struck a deal to cement their status as two of the hottest players in the new wave of biotech startups. The one-year agreement sees Twist sign up to supply Ginkgo with 100 million base pairs of synthetic DNA.

FDA adds another artificial kidney to its Expedited Access Pathway program

A surgically implanted artificial kidney under development at the University of California, San Francisco, has been accepted into the FDA's Expedited Access Pathway for "breakthrough" technologies that debuted just 6 months ago.